Priovant Therapeutics Receives FDA Approval for Brepocitinib to Treat Dermatomyositis
Priovant Therapeutics has received U.S. Food and Drug Administration (FDA) approval for its lead drug, Lisraya (brepocitinib), as a treatment for dermatomyositis—a rare autoimmune disorder marked by muscle weakness and skin lesions. The once-daily oral medication is the first FDA-approved therapy specifically targeting this condition. The approval marks a significant milestone for Priovant, which is backed by Roivant Sciences (ROIV) and Pfizer (PFE). Brepocitinib's regulatory clearance could position it as an important treatment option in a niche but high-need therapeutic area. The drug’s availability may also enhance the market presence of both Roivant and its parent company. This development is expected to attract attention from investors, particularly given the involvement of major pharmaceutical players like Pfizer.
